SuperworthVistagen Therapeutics VTGN
- Market cap
- $8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Vistagen Therapeutics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $277.7K | $411.4K | $197.3K | $84K−53% | $183K−34% | $234K−43% | n/a | $244K+191% | $258K+41% | $303K+30% | n/a | $1.5M+505% | |
| R&D | $3.9M−70% | $4.5M−34% | $7.4M−20% | $7.6M+82% | $10.2M+165% | $11.3M+149% | n/a | $11.7M+53% | $15.9M+56% | $14.2M+26% | n/a | $10.9M−7% |
| SG&A | $3.2M−13% | $3.8M+22% | $4.1M+34% | $4.6M+53% | $4.2M+31% | $4M+8% | n/a | $4.4M−4% | $4.4M+5% | $5.6M+39% | n/a | $3.9M−10% |
| −$6.8M−61% | −$7.9M−19% | −$11.4M−7% | −$12.1M+73% | −$14.2M+110% | −$15.1M+92% | n/a | −$15.8M+30% | −$20.1M+41% | −$19.5M+29% | n/a | −$13.3M−16% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$6.6M−62% | −$6.3M−35% | −$9.5M−22% | −$10.7M+56% | −$13M+97% | −$14.1M+122% | n/a | −$15.1M+41% | −$19.4M+50% | −$18.9M+34% | n/a | −$13M−14% |
| $0 | $0 | $1.5K+50% | $0 | $7K | $0 | n/a | $0 | $0 | $0 | n/a | $0 | |
| Net income | −$6.6M−62% | −$6.3M−35% | −$9.5M−22% | −$10.7M+56% | −$13M+97% | −$14.1M+122% | −$13.6M+43% | −$15.1M+41% | −$19.4M+50% | −$18.9M+34% | −$16.3M+19% | −$13M−14% |
| −$0.66 | −$0.22 | −$0.31 | −$0.35−63% | −$0.42−36% | −$0.46+109% | −$0.43+39% | −$0.47+34% | −$0.54+29% | −$0.45−2% | −$0.38−12% | −$0.30−36% | |
| 10M | 29.4M | 30.6M | 30.6M+317% | 30.6M+205% | 30.7M+5% | 31.6M+3% | 31.9M+4% | 35.7M+17% | 42.2M+38% | 42.4M+34% | 43M+35% |
EPS, diluted: 7 periods, Q4 FY11 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY11: share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY16 to Q4 FY26: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Vistagen Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| VTGNVistagen Therapeutics | $8M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Vistagen Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .